BioSpace News Archive

Medivir AB announced today that its partner Vetbiolix, a veterinary biotechnology company based in France , reported positive results from a Proof-of-Concept clinical study in periodontal disease in dog with its drug candidate VBX-1000, previously known as MIV-701.

Outset Medical, Inc. today announced its partnership with the American Nephrology Nurses Association (ANNA) as a member of its new Partnership Advisory Council.

TransCode Therapeutics, Inc. announced today that the U.S. Food and Drug Administration (FDA) has completed its review of the company’s Investigational New Drug (IND) application and concluded that the company may proceed with its Phase 1/2 multicenter, open-label, dose-escalation and dose-expansion study of its lead therapeutic candidate.

Tharimmune, Inc. announced today the formation of a new Scientific Advisory Board (SAB).

Applied BioCode now offers STI + Resistance Panel on the BioCode® MDx-3000 system for research use only (RUO).

Nika Pharmaceuticals, Inc. (OTCMKTS: NKPH ) announces the purchase of four technologies for production of three generic drugs in tablet form and one dietary supplement.

According to Nova One Advisor, the global biologics contract development market size was accounted for USD 8.49 billion in 2023 and it is increasing around USD 18.68 billion by 2033 with a CAGR of 8.2% from 2024 to 2033.

Imugene Limited (ASX: IMU), a clinical stage immuno-oncology company, is pleased to announce that enrolment has opened for its expansion study in bile tract cancer (cholangiocarcinoma) patients, having completed the fifth, high dose cohort in the intratumoural (IT) arm of the monotherapy dose escalation study evaluating its cancer-killing virus CF33-hNIS (VAXINIA).

Telix Pharmaceuticals Limited announces that the United States Food and Drug Administration has granted Fast Track designation for the Company’s investigational glioma imaging product, TLX101-CDx.

Immix Biopharma, Inc. today announced that updated NXC-201 clinical data has been selected for presentation at the upcoming 27th Annual Meeting of The American Society of Gene & Cell Therapy (ASGCT) to be held in Baltimore May 7-11, 2024.